Section Review: The rate-limiting step in obtaining human monoclonal antibody drug pharmaceuticals:Biologicals & Immunologicals

Abstract

A high priority for those in the pharmaceutical industry is the discovery and design of novel drugs with clinical merit. In most instances, years and significant expenditure of precious resources are spent in the testing and validation of these drugs. A clear understanding of the steps involved in producing them, in particular the rate limiting steps, will benefit all and ultimately result in less expensive drugs which reach the marketplace faster. It is clear that some of the next generation of drugs, with improved specificity and efficacy, will come from the rapidly developing biotechnology industry.